Simple jQuery Dropdowns

Statistics

Total Visits

Views
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC 63

Total Visits per Month

November 2021 December 2021 January 2022 February 2022 March 2022 April 2022 May 2022
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC 0 3 0 0 1 1 0

File Downloads

Views

Top Country Views

Views

Top City Views

Views